Ignyta Announces New Data Highlighting Immune Modulation of RXDX-106 at the Society for Immunotherapy of Cancer (SITC) Meeting
09 November 2017 - 12:00AM
Business Wire
Ignyta, Inc. (Nasdaq: RXDX), a biotechnology
company focused on precision medicine in oncology, today announced
new preclinical data for RXDX-106 – a novel immunomodulatory agent
that demonstrated potent anti-tumor activity, alone and in
combination with checkpoint inhibitors, by modulating the tumor
microenvironment (TME) through TYRO3, AXL, and MER (TAM) receptor
tyrosine kinase (RTK) inhibition. In the TME, TAM RTKs contribute
to cancer cell evasion of the immune system and progression by
promoting anti-inflammatory and pro-tumorigenic activities.
RXDX-106 is a potent and selective TAM inhibitor in late-stage
preclinical development, designed to reverse TAM RTKs-mediated
immunosuppression and inhibit tumor growth and progression. The
data were presented in two posters (abstracts P90 and P473) at the
32nd Annual SITC Meeting, in National Harbor, Maryland.
"We are excited by the immunomodulatory effects of RXDX-106
observed in a variety of preclinical models, and its potential to
elicit and potentiate an immune response to cancer, both as a
single agent and combined with checkpoint inhibitors,” said
Jonathan Lim, M.D., chairman and CEO of Ignyta. “RXDX-106
represents a new class of immuno-oncologic precision medicines by
targeting the TAM RTKs in the tumor microenvironment. We look
forward to bringing it into clinical trials in early 2018 to
continue our efforts to help patients in their fight against
cancer.”
Using complementary approaches, including gene and protein
modulation, RXDX-106 treatment resulted in the recruitment of both
innate and adaptive immune cell subtypes to the TME. Using RNA
sequencing, differential expression of immunomodulatory genes were
observed in RXDX-106 treated compared to vehicle treated mouse
cohorts, indicative of an enrichment in
pro-inflammatory/anti-tumorigenic immune cell infiltration. In
addition, RXDX-106 demonstrated immune-mediated, single-agent
anti-tumor activity in multiple tumor models that was further
enhanced by combination therapy with immune checkpoint inhibitors.
These data further demonstrate the ability of RXDX-106 to activate
both innate and adaptive immunity, as observed by
treatment-mediated changes in relevant cytokine levels and immune
cell biomarkers, and regulating cross-talk between immune and
cancer cells. These promising early findings support further
development of RXDX-106 to potentially treat a wide variety of
cancers.
About Ignyta, Inc.
Blazing a New Future for Patients with
Cancer™
At Ignyta, we work tirelessly on behalf of patients with
cancer to offer potentially life-saving, precisely targeted
therapeutics (Rx) guided by diagnostic (Dx) tests. Our integrated
Rx/Dx strategy allows us to enter uncharted territory, illuminating
the molecular and immunological drivers of cancer and quickly
advancing treatments to address them. This approach embraces even
those patients with rare cancers, who have the highest unmet need
and who may otherwise not have access to effective treatment
options. With our pipeline of potentially first-in-class or
best-in-class precision medicines, we are pursuing the ultimate
goal of not just shrinking tumors, but eradicating cancer relapse
and recurrence in precisely defined patient populations.
For more information, please visit: www.ignyta.com.
Forward-Looking Statements
This press release contains forward-looking statements
about Ignyta as that term is defined in Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Statements in this press release that are not
purely historical are forward-looking statements. Such
forward-looking statements include, among other things: references
to the development of RXDX-106, the preclinical data or plans
underlying RXDX-106, our ability to design and conduct development
activities for RXDX-106, the timeline associated with such
development program and the potential efficacy of RXDX-106. Actual
results could differ from those projected in any forward-looking
statements due to numerous factors. Such factors include, among
others, the inherent uncertainties associated with developing new
products or technologies and operating as a development stage
company; Ignyta's ability to develop, initiate or
complete preclinical studies and clinical trials for, obtain
approvals for and commercialize any of its product candidates;
changes in Ignyta's plans to develop and commercialize
its product candidates; the potential for final results of the
ongoing clinical trials of entrectinib or other product candidates,
or any future clinical trials of entrectinib or other product
candidates, to differ from preliminary or expected
results; Ignyta's ability to raise any additional funding
it will need to continue to pursue its business and product
development plans; regulatory developments in the United
States and foreign countries; our dependence on third party
manufacturers for supply of our product candidates and any approved
products; Ignyta's ability to obtain and maintain
intellectual property protection for its product candidates; the
risk that orphan drug exclusivity may not effectively protect a
product from competition and that such exclusivity may not be
maintained; the potential for the company to fail to maintain the
CAP accreditation and CLIA certification of its diagnostic
laboratory; the loss of key scientific or management personnel;
competition in the industry in which Ignyta operates; and
market conditions. These forward-looking statements are made as of
the date of this press release, and Ignyta assumes no
obligation to update the forward-looking statements, or to update
the reasons why actual results could differ from those projected in
the forward-looking statements. Investors should consult all of the
information set forth herein and should also refer to the risk
factor disclosure set forth in the reports and other documents the
company files with the SEC available at www.sec.gov,
including without limitation Ignyta's Annual Report on
Form 10-K for the year ended December 31, 2016 and
subsequent Quarterly Reports on Form 10-Q.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171108005395/en/
Ignyta, Inc.Jacob Chacko, M.D.CFO858-255-5959jc@ignyta.com
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Apr 2024 to May 2024
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From May 2023 to May 2024